Metabolic syndrome represents a collection of metabolic problems associated with obesity, such as hy...

Metabolic disorders which increase excretion of solutes - eg, chronic metabolic acidosis, hypercalciuria, hyperuricosuria.

Metabolic disorders which increase the excretion of solutes, e.g. chronic metabolic acidosis, hypercalciuria, hyperuricosuria.

Metabolic syndrome represents a collection of metabolic problems associated with obesity, such as hy...

To get a metabolic syndrome diagnosis, you would present at least three metabolic disorders.

Metabolic acid-base disorders result in respiratory compensation (change in P co 2); respiratory acid-base disorders result in metabolic compensation (change in HCO 3 −).

Metabolic acid-base disorders result in respiratory compensation (change in P co 2); respiratory acid-base disorders result in metabolic compensation (change in HCO 3 −).

Inhibitors of the type 1 isoform (11β -HSD1) may be useful to treat type 2 diabetes, Metabolic Syndrome, and other metabolic disorders.

The present invention relates to animal models of metabolic disorders such as obesity, diabetes, metabolic syndrome, insulin resistance, hyperinsulinemia, glucose intolerance, hyperlipidemia, and the like.

The metabolic disorders are associated with hypertriglyceridemia, overweight, obesity, diabetes, hypertension, liver cirrhosis, metabolic syndrome and combinations thereof.

Metabolic syndrome - interconnected metabolic, hormonal and clinical disorders, which are high-risk factors for the development of diseases of the cardiovascular system.

Metabolic disorders such as diabetes and metabolic syndrome can block blood flow to and from the heart.

The embodiments further provide treatment methods, including method of treating metabolic disorders and metabolic disorders selected from metabolic syndrome, diabetes and obesity.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented.

The present invention relates to fish-protein hydroysates used in preventing and/or treating metabolic disorders, such as metabolic syndrome particularly associated with obesity.